|1.||Qualls, Clifford R: 1 article (01/2010)|
|2.||Archibeque, Tereassa: 1 article (01/2010)|
|3.||Wilson, Bridget S: 1 article (01/2010)|
|4.||Tarleton, Christy A: 1 article (01/2010)|
|5.||Schuyler, Mark: 1 article (01/2010)|
|6.||Oliver, Janet M: 1 article (01/2010)|
|7.||Diehl, Lorena: 1 article (01/2010)|
|8.||Gilmartin, Laura: 1 article (01/2010)|
|9.||Lee, D K C: 1 article (08/2004)|
|10.||Chazan, Ryszarda: 1 article (06/2003)|
|1.||Asthma (Bronchial Asthma)
06/01/2000 - "rhuMAb-E25 is well tolerated and has shown promising results in improving symptoms and lung function in patients with moderate to severe asthma. "
07/25/2000 - "The clinical safety and efficacy of rhuMAb-E25 demonstrated in phase II studies of allergic asthma will be outlined."
12/23/1999 - "We studied the efficacy of rhuMab-E25 as a treatment for moderate-to-severe allergic asthma. "
06/01/2000 - "Recent clinical studies in subjects with asthma have shown that rhuMAb-E25 attenuates both the early and late phase responses to inhaled allergen, and reduces the associated increase in eosinophils in induced sputum. "
03/01/2002 - "rhuMAb-E25 has been shown to reduce allergic responses in atopic individuals and to improve symptoms and reduce rescue medication and corticosteroid use in patient with allergic asthma. "
10/01/2001 - "In clinical trials, the therapy with rhuMAb-E25 was effective in patients with atopic asthma and allergic rhinitis and well tolerated. "
07/01/1997 - "Two hundred forty subjects were enrolled into five groups to determine the safety, tolerance, and efficacy of repeated administration of rhuMAb-E25 in adults with ragweed-induced allergic rhinitis and to explore the pharmacodynamic relationship of rhuMAb-E25 and IgE. "
08/01/2004 - "The role of omalizumab or rhuMAB-E25 in the treatment of allergic rhinitis."
|3.||Lung Diseases (Lung Disease)
03/01/2002 - "The clinical effectiveness of rhuMAb-E25 supports the central role of IgE in allergic reaction and the viability of anti-IgE therapy as an effective immunological intervention for allergic asthma."
11/01/2000 - "Thus, the clinical effectiveness of rhuMAb-E25 supports the central role of IgE in allergic reactions and the viability of anti-IgE therapy as a potentially effective treatment option for asthma."
|5.||Body Weight (Weight, Body)
07/01/1997 - "One hundred eighty-one subjects received an initial intravenous loading dose (day 0, 1 month before ragweed season), followed by administration of rhuMAb-E25 (in mg/kg body weight) of 0.15 mg/kg subcutaneously, 0.15 mg/kg intravenously, or 0.5 mg/kg intravenously on days 7, 14, 28, 42, 56, 70, and 84. "
12/23/1999 - "After a 4-week run-in period, we randomly assigned 317 subjects (age range, 11 to 50 years) who required inhaled or oral corticosteroids (or both) to receive either placebo or one of two regimens of rhuMAB-E25: high-dose rhuMAb-E25 (5.8 microg per kilogram of body weight per nanogram of IgE per milliliter or low-dose rhuMAb-E25 (2.5 microg per kilogram per nanogram of IgE per milliliter) intravenously on days 0 (half a dose), 4 (half a dose), and 7 (full dose) and then once every 2 weeks thereafter for 20 weeks. "
|1.||Immunoglobulin E (IgE)
|4.||Adrenal Cortex Hormones (Corticosteroids)
|5.||Interleukin-4 Receptors (Interleukin 4 Receptor)
|7.||Interleukin-12 (IL 12)